Bacterial meningitis in older adults

Current Treatment Options in Neurology

Volumn 15, Issue 4, 2013, Pages 477-491

  Hofinger, Diedre ^a,b   Davis, Larry E ^a,b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Acute; Antimicrobial therapy; Bacterial meningitis; Community acquired; Comorbidities; Elderly; Gram negative bacilli; Healthcare associated meningitis; Listeria monocytogenes; Neisseria meningitidis; Nosocomial meningitis; Older adults; Staphylococcus; Streptococcus pneumoniae; Treatment

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPTOMYCIN; DEXAMETHASONE; LINEZOLID; MENINGOCOCCUS VACCINE; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PNEUMOCOCCUS VACCINE; POLYMYXIN B; PROBENECID; RIFAMPICIN; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER INFECTION; ADJUVANT THERAPY; ADULT; AGRANULOCYTOSIS; ANAPHYLAXIS; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APLASTIC ANEMIA; ARTICLE; ATAXIA; BACTERIAL MENINGITIS; BLOOD CULTURE; BLOOD TOXICITY; BLURRED VISION; BONE MARROW SUPPRESSION; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID CULTURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DAIRY PRODUCT; DIARRHEA; DIZZINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA MULTIFORME; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM STAINING; GRANULOCYTOPENIA; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS MENINGITIS; HEALTHCARE ASSOCIATED INFECTION; HEARING IMPAIRMENT; HEMOLYTIC ANEMIA; HUMAN; HYPERKALEMIA; INTERSTITIAL NEPHRITIS; KLEBSIELLA PNEUMONIAE INFECTION; LACTIC ACIDOSIS; LEUKOPENIA; LISTERIA MONOCYTOGENES; LISTERIOSIS; LIVER FUNCTION TEST; LOADING DRUG DOSE; LUMBAR PUNCTURE; MENINGOCOCCOSIS; MENINGOCOCCUS MENINGITIS; METHEMOGLOBINEMIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS MENINGITIS; MILK; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; NAUSEA; NEISSERIA MENINGITIDIS; NEPHROTOXICITY; NEUROIMAGING; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIC NERVE DISEASE; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PRURITUS; PSEUDOMONAS INFECTION; PSEUDOMONAS MENINGITIS; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SLOW BRAIN WAVE; SLURRED SPEECH; STAPHYLOCOCCUS AUREUS; STEVENS JOHNSON SYNDROME; STREPTOCOCCUS PNEUMONIAE; TENDON RUPTURE; THROMBOCYTOPENIA; THROMBOCYTOSIS; TOXIC EPIDERMAL NECROLYSIS; VERTIGO; VOMITING;

EID: 84882276444     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-013-0244-7     Document Type: Article

References (78)

1. McIntyre PB, O'Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet. 2012;380:1703-11. This is a review summarizing the effect of vaccines on meningitis worldwide.
2. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011;364:2016-25.
3. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995, Active surveillance team. N Engl J Med. 1997;337:970-6.
4. Rasmussen HH, Sorensen HT, Moller-Peterson J, et al. Bacterial meningitis in elderly patients: Clinical picture and course. Age and Ageing. 1992;21:216-20.
5. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med. 1993;328:21-8.
6. Begg N, Cartwright KAV, Cohen J, et al. Consensus statement on diagnosis, investigation, treatment, and prevention of acute bacterial meningitis in immunocompetent adults. J Infect. 1999;39:1-15.
7. Cabellos C, Verdaguer R, Olmo M, et al. Community-acquired bacterial meningitis in elderly patients. Experience over 30 years. Medicine. 2009;88:115-9.
8. Khassawneh FA, Smalligan RD, Mohamad TN, et al. Lumbar puncture for suspected meningitis after intensive care unit admission is likely to change management. Hosp Pract. 2011;39:141-5.
9. Jackson WL, Shorr AF. The yield of lumbar puncture to exclude nosocomial meningitis as aetiology for mental status changes in the medical intensive care unit. Anaesth Intensive Care. 2006;34:21-4.
10. Laxmi S, Tunkel A. Healthcare-associated bacterial meningitis. Curr Infect Dis Rep. 2011;13:367-73. This is a review article discussing the new term healthcare-associated meningitis.
11. Lai W, Chen S, Tsai N, et al. Clinical characteristics and prognosis of acute bacterial meningitis in elderly patients over 65: a hospital-based study. BMC Geriatr. 2011;11:91-6. This is a retrospective review of bacterial meningitis in elderly patients.
12. Chang WN, Huang CR, Lu CH, Chien CC. Adult Klebsiella pneumoniae meningitis in Taiwan: An overview. Acta Neurol Taiwan. 2012;21:87-96.
13. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med. 2010;362:146-54. This review article discusses in depth nosocomonial bacterial meningitis, organisms involved and treatments.
14. Conen A, Walti LN, Merlo A, et al. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis. 2008;47:73-82.
15. Lu CH, Chang WN, Chuang YC, Chang HW. Gram-negative bacillary meningitis in adult post-neurosurgical patients. Surg Neurol. 1999;52:438-43.
16. McClelland S, Hall WA. Postoperative central nervous system infection: incidence and associated factors in 2111 neurosurgical procedures. Clin Infect Dis. 2007;45:55-9.
17. Domingo P, Pomar V, DeBenito N, et al. The spectrum of acute bacterial meningitis in elderly patients. BMC Infect Dis. 2013;13:108-17.
18. van Crevel H, Hijdra A, de Gans J. Lumbar puncture and the risk of herniation: when should we first perform CT? J Neurol. 2002;249:129-37.
19. Feigin RD, Stechenberg BW, Chang MJ, et al. Prospective evaluation of treatment of Haemophilus influenzae meningitis. J Pediatr. 1976;88:542-8.
20. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for management of bacterial meningitis. Clin Infect Dis. 2004;39:1267-84.
21. Hasbun R, Abrahams J, Jekel J, et al. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med. 2001;345:1727-33.
22. Auburtin M, Wolf M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med. 2006;34:2758-65.
23. Greig PR, Goroszeniuk D. Role of computed tomography before lumbar puncture: a survey of clinical practice. Postgrad med J. 2006;82:162-5.
24. Brouwer MC, Thwaites GE, Turkel AR, van de Beak D. Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. Lancet. 2012;380:1684-92. This review article discusses diagnostic dilemmas that are common with bacterial meningitis.
25. Talan DA, Guterman JJ, Overturf GD, et al. Analysis of emergency department management of suspected bacterial meningitis. Ann Emerg Med. 1989;18:856-62.
26. Proulx N, Fre'chette D, Toye B, Chan J, Kravcik S. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM Int J med. 2005;98:291-8.
27. Schut ES, de Gans J, van de Beak D. Community-acquired bacterial meningitis in adults. Pract Neurol. 2008;8:8-23.
28. de Gans J, Van de Beak D. European Dexamethasone in adulthood bacterial meningitis study investigators.: Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347:1549-56.
29. Centers for Disease Control and Prevention. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae - United States, 2006-2007. MMWR Morb Mortal Wkly Rep. 2008;57:1353-5.
30. van de Beek D, Brouwer MC, Thwaites GE, et al. Advances in treatment of bacterial meningitis. Lancet. 2012;380:1693-702. This review article discusses basic principles and treatment of bacterial meningitis.
31. Bartlett JG, Pham PA. John Hopkins Abx guide. Diagnosis and treatment of infectious disease. In: Bartlett JG, Auwaeter PG, Pham PA, editors. Antibiotics. Massachusetts: Jones and Bartlett Learning; 2012. p. 473-661.
32. Chang C, Mahmood MM, Teuber SS, et al. Overview of penicillin allergy. Clin Rev Allergy Immunol. 2012;43:84-97.
33. Frank M. Systemic and CNS toxicities of antimicrobial agents. Central nervous System Infectious Diseases and Therapy. Edited by Roos KL. New York: Marcel Dekker; 1987:711-730.
34. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23:858-83.
35. Ricard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis. 2007;44:250-5.
36. Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis: Meropenem Meningitis Study Group. Antimicrob Agents Chemother. 1995;39:1140-6.
37. Latorre C, Gené A, Juncosa T, Muñoz C, González- Cuevas A. Neisseria meningitidis: evolution of penicillin resistance and phenotype in a children's hospital in Barcelona, Spain. Acta Paediatr. 2000;89:661-5.
38. Richter SS, Gordon KA, Rhomberg PR, et al. Neisseria meningitidis with decreased susceptibility to penicillin: Report from Sentry antimicrobial surveillance program, North America, 1998-1999. Diag Microb Infect Dis. 2001;41:83-8.
39. Wu HM, Harcourt BH, Hatcher CP, et al. Emergence of ciprofloxacin- resistant Neisseria meningitidis in North America. N Engl J Med. 2009;360:886-92.
40. Lapadula G, Viganò F, Fortuna P, et al. Imported ciprofloxacin-resistant Neisseria meningitidis. Emerg Infect Dis. 2009;15:1852-4.
41. Cottagnoud P, Täuber M. Fluoroquinolones in the Treatment of Meningitis. Curr Infect Dis Rep. 2003;5:329-36.
42. Darabi A, Hocquet D, Dowzicky MJ. Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial. Diagn Microbiol Infect Dis. 2010;67:78-86.
43. Sum L, Gomolin I. Cefepime neurotoxicity: Case report, pharmacokinetic considerations and literature review. Pharmacotherpy. 2006;26:1169-74.
44. Chow KM, Szeto CC, Hui AC. Retrospective review of neurotoxicity induced by cefepime and cetazidime. Pharmacotherapy. 2003;23:369-73.
45. Amaya-Villar R, García-Cabrera E, Sulleiro-Igual E, et al. Three-year multicenter surveillance of community acquired Listeria monocytogenes meningitis in adults. BMC Infect Dis. 2010;10:324-32.
46. Moragas M, Martínez-Yélamos S, Majós C, et al. Rhombencephalitis: a series of 97 patients. Medicine. 2011;90:256-61.
47. Lu CH, Chang WN, Chuang YC, Chang HW. The prognostic factors of adult Gram-negative bacillary meningitis. J Hosp Infect. 1998;40:27-34.
48. Kim HI, Kim SW, Park GY, et al. The causes and treatment outcomes of 91 patients with adult nosocomial meningitis. Korean J Intern Med. 2012;27:171-9.
49. Garnach-Montero J, Amaya-Willar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis. 2010;23:332-9.
50. Falagas ME, Bliziotio IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents. 2007;29:9-25.
51. Katragdou A, Roilides E. Successful treatment of multidrug resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbial. 2005;43:4916-7.
52. Huang CR, Lu CH, Chuang YC, et al. Adult Pseudomonas aeruginosa meningitis: high incidence of underlying medical and/or post neurosurgical conditions and high mortality rate. Jpn J Infect Dis. 2007;60:397-9.
53. Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother. 2009;53:4907-10.
54. Segal-Maurer S, Mariano N, Qavi A, et al. Successful treatment of ceftaxidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis. 1999;28:1134-8.
55. Quinn AL, Parada JP, Belmares J, et al. Intrathecal colistin and sterilization of resistant Pseudomonase aeruginosa shunt infection. Ann Pharmacother. 2005;39:949-52.
56. Aguilar J, Urday-Cornejo V, Donabedian S. Staphylococcus aureus meningitis: case series and literature review. Medicine. 2010;89:117-25. This is a retrospective review to help establish guidelines for the treatment of S. aureus meningitis.
57. Liu C, Bayer A, Cosgrove S, et al. Management of Patients with Infections Caused by Methicillin-Resistant Staphylococcus Aureus: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2011;52:1-38. This is a review to establish the IDSA guidelines for patients with MRSA infections.
58. Teh BW, Slavin MA. Staphylococcus aureus meningitis: barriers to treatment. Leuk Lymphoma. 2012;53:1443-4.
59. Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. Clin Infect Dis. 2008;44:1356-8.
60. Bardak-Ozcem S, Turhan T, Sipahi OR, et al. Daptomycin versus vancomycin in treatment of methicillin-resistant Staphylococcus aureus meningitis in an experimental rabbit model. Antimicrob Agents Chemother. 2013;57:1556-8.
61. Wahby K, Alangaden GJ. Daptomycin failure in a neutropenic leukemia patient with Staphylococcus aureus meningitis. Leuk Lymphoma. 2012;53:1610-2.
62. Beringer P, Nguyen M, Hoem N, et al. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005;49:3676-81.
63. Weisfelt M, van de Beek D, Spanjaard L, et al. Community-acquired bacterial meningitis in older people. JAGS. 2006;54:1500-7.
64. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol. 2010;9:254-63. This is a meta-analysis to determine which patients benefit from dexamethasone therapy.
65. Nguyen TH, Tran TH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med. 2007;357:2431-40.
66. Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med. 2007;357:2441-50.
67. Molyneux EM, Walsh AL, Forsyth H, et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomized controlled trial. Lancet. 2002;360:211-18.
68. Brouwer MC, McIntyre P, de Gans J, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2010;9:CD004405.
69. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244-56.
70. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCY7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346-54.
71. Centers for Disease Control and Preventions. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-9. This is a statement from the CDC to establish recommendations for vaccinations in adults.
72. Vila-Córcoles A, Ochoa-Gondar O, Guzmán JA, et al. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect Dis. 2010;10:73-81.
73. O'Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: Hospital case characteristics and costs by age. Value Health. 2006;9:236-43.
74. Stephens DS, Hajjeh RA, Baughman WS, et al. Sporadic meningococcal disease in adults: Results of a 5-year population-based study. Ann Intern Med. 1995;123:937-40.
75. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: Implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184-91.
76. Stephens DS. Uncloaking the Meningococcus: dynamics of carriage and disease. Lancet. 1999;353:941-2.
77. CDC. Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2011;60:72-6.
78. Macneil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30:451-5. This study reports the early estimate of the vaccines effectiveness and the numbers of breakthrough disease.